Literature DB >> 12464596

DNA-PKcs expression in esophageal cancer as a predictor for chemoradiation therapeutic sensitivity.

Tsuyoshi Noguchi1, Tomotaka Shibata, Shoichi Fumoto, Yuzo Uchida, Wolfram Mueller, Shinsuke Takeno.   

Abstract

BACKGROUND: It would be of considerable benefit to patients with esophageal cancer to be able to predict the effect of CRT before therapy, because critical side effects could be avoided and the therapeutic cost of CRT-resistant cases could be reduced. One of the biological parameters with the potential to indicate radioresponse is the DNA double-strand break repair enzyme DNA-PKcs. This study aims to clarify the correlation between DNA-PKcs expression and CRT effect.
METHODS: Sixty-seven patients with progressive esophageal cancer treated with CRT were included in this study. The relationship between the expression of DNA-PKcs and the effect of CRT was examined by using immunohistochemistry. The relationships between DNA-PKcs expression, clinicopathologic parameters, and CRT effect were investigated statistically.
RESULTS: A significant correlation was found between the expression of DNA-PKcs and the effect of CRT (P =.0149). The high-DNA-PKcs expression group showed greater therapeutic sensitivity than the low-expression group. Clinicopathologic factors had no relationship with DNA-PKcs expression or CRT effect.
CONCLUSIONS: This study suggests that high expression of DNA-PKcs correlates with CRT effect. DNA-PKcs expression could, therefore, be useful for predicting the effect of CRT. In addition, these results may make it possible to plan therapy taking patients' quality of life into consideration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12464596     DOI: 10.1007/bf02574522

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  9 in total

Review 1.  Genotypic characteristics of resistant tumors to pre-operative ionizing radiation in rectal cancer.

Authors:  Zeeshan Ramzan; Ammar B Nassri; Sergio Huerta
Journal:  World J Gastrointest Oncol       Date:  2014-07-15

2.  Targeting DNA-PKcs increased anticancer drug sensitivity by suppressing DNA damage repair in osteosarcoma cell line MG63.

Authors:  Xin Li; Jiguang Tian; Qiyu Bo; Ka Li; Hongliang Wang; Ting Liu; Jianmin Li
Journal:  Tumour Biol       Date:  2015-06-25

3.  Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis.

Authors:  Hai-Lin Jin; Hong Zhu; Ting-Sheng Ling; Hong-Jie Zhang; Rui-Hua Shi
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

4.  Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment.

Authors:  Feng-Ming Hsu; Shichuan Zhang; Benjamin P C Chen
Journal:  Transl Cancer Res       Date:  2012-05-22       Impact factor: 1.241

Review 5.  The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer.

Authors:  Brock J Sishc; Anthony J Davis
Journal:  Cancers (Basel)       Date:  2017-07-06       Impact factor: 6.639

6.  Gαi3 nuclear translocation causes irradiation resistance in human glioma cells.

Authors:  Shang Cai; Ya Li; Jin-Yu Bai; Zhi-Qing Zhang; Yin Wang; Yin-Biao Qiao; Xiao-Zhong Zhou; Bo Yang; Ye Tian; Cong Cao
Journal:  Oncotarget       Date:  2017-05-23

7.  Potential value of PRKDC as a therapeutic target and prognostic biomarker in pan-cancer.

Authors:  Xiawei Yang; Feng Yang; Liugen Lan; Ning Wen; Haibin Li; Xuyong Sun
Journal:  Medicine (Baltimore)       Date:  2022-07-08       Impact factor: 1.817

8.  Nuclear survivin and its relationship to DNA damage repair genes in non-small cell lung cancer investigated using tissue array.

Authors:  Songliu Hu; Yuanyuan Qu; Xiangying Xu; Qingyong Xu; Jingshu Geng; Jianyu Xu
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

9.  Deregulation of DNA-dependent protein kinase catalytic subunit contributes to human hepatocarcinogenesis development and has a putative prognostic value.

Authors:  M Evert; M Frau; M L Tomasi; G Latte; M M Simile; M A Seddaiu; A Zimmermann; S Ladu; T Staniscia; S Brozzetti; G Solinas; F Dombrowski; F Feo; R M Pascale; D F Calvisi
Journal:  Br J Cancer       Date:  2013-10-17       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.